1030 Massachusetts Avenue
About Jounce Therapeutics
Jounce Therapeutics is focused on the discovery and development of novel cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
This transformational approach has the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life.
Jounce is building upon the unparalleled expertise of its renowned scientific founders – world leaders in the fields of immunology, cancer biology and clinical and translational medicine in cancer – and its increasing understanding of how cancer cells communicate and interact with the immune system to position the company at the forefront of cancer immunotherapy drug discovery and development.
Based in Cambridge, Mass., Jounce is a private company launched in 2013 with $47 million in Series A venture capital financing by Third Rock Ventures.
126 articles about Jounce Therapeutics
Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Robert Iannone, M.D., M.S.C.E., to its board of directors.
Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jounce Therapeutics, Inc. announced that Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 8:00 AM PT in San Francisco.
Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from the vopratelimab ICONIC trial, on the association of a predictive RNA signature with the emergence of ICOS hi CD4 T cells and clinical outcomes
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial
Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2019 financial results and provide a corporate update before market open on Thursday, November 7, 2019.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
BioSpace Movers and Shakers for Oct. 15
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
A look at three biotech companies that face make-or-break catalysts this year.
Jounce Therapeutics Added to NASDAQ Biotechnology Index
The addition will take effect prior to the open of the U.S. markets on Monday, December 18, 2017.
Jounce Therapeutics Reports Third Quarter 2017 Financial Results
Jounce has narrowed its financial guidance previously provided for the full year 2017.
Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
Dr. Diaz brings to the company his world-renowned expertise in cancer genetics and a precision medicine approach to immuno-oncology.
Jounce Names Ex-Ariad's Top Dealmaker as Its New CBO
Jounce Reports Second Quarter 2017 Financial Results